Stem cell treatment for Parkinson's disease: An update for 2005

Current Opinion in Neurology

Volumn 18, Issue 4, 2005, Pages 376-385

  Snyder, Brian J ^a   Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Neural transplantation; Parkinson's disease; Stem cell

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FIBROBLAST GROWTH FACTOR 8; HORMONE RECEPTOR BLOCKING AGENT; LEVODOPA; SONIC HEDGEHOG PROTEIN;

AUTONOMIC DYSFUNCTION; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL TRIAL; DEMENTIA; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSKINESIA; EMBRYONIC STEM CELL; GRAFT SURVIVAL; HUMAN; MOOD DISORDER; MOTOR DYSFUNCTION; NEURAL STEM CELL; NONHUMAN; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; STEM CELL; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; TERATOMA; WITHDRAWAL SYNDROME;

EID: 23344449323     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000174298.27765.91     Document Type: Review

References (54)

1. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders - how to make it work. Nat Med 2004; 10:542-550. This paper elegantly summarizes the current knowledge and procedures for generating dopamine neurons from the different types of stem cells.
2. Freed CR. Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease? Proc Natl Acad Sci USA 2002; 99:1755-1757.
3. Braak H, Tredici KD, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211.
4. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339:1044-1053.
5. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55:259-272.
6. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56 (suppl 5):1-88.
7. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291:358-364. This paper reviews current approaches to neuroprotection for Parkinson's disease.
8. Olanow CW, Freeman TB, Kordower JH. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19:102-109.
9. Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177:555-560.
10. Perlow MJ, Freed WJ, Hoffer BJ, et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979; 204:643-647.
11. Redmond DE, Sladek JR Jr, Roth RH, et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1986; 1:1125-1127.
12. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992; 327:1549-1555.
13. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247:574-577.
14. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31:155-165.
15. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's Disease. Ann Neurol 1995; 38:379-388.
16. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2:1137-1140.
17. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathologic evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332:1118-1124.
18. Kordower JH, Rosenstein JM, Collier TM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, quantitative, ultrastructural, and metabolic studies. J Comp Neurol 1996; 370:203-230.
19. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344:710-719.
20. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54:403-414.
21. Fink JS, Schumacher JM, Ellias SL, et al. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant 2000; 9:273-278.
22. Bakay RA, Raiser CD, Stover NP, et al. Implantation of Spheramine in advanced Parkinson's disease (PD). Front Biosci 2004; 9:592-602.
23. Doss MX, Koehler CI, Gissel C, et al. Embryonic stem cells: a promising tool for cell replacement therapy. J Cell Mol Med 2004; 8:465-473.
24. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99:2344-2349. This paper demonstrates elegantly that transplanted embryonic stem cells can survive and differentiate spontaneously into dopamine neurons and provide behavioral benefits in the 6-OHDA rodent.
25. Storch A, Sabolek M, Milosevic J, et al. Midbrain-derived neural stem cells: from basic science to therapeutic approaches. Cell Tissue Res 2004; 318:15-22. This is a detailed and thorough scientific review of the factors needed to develop neural stem cells for transplantation.
26. Magavi SS, Macklis JD. Manipulation of neural precursors in situ: induction of neurogenesis in the neocortex of adult mice. Neuropsychopharmacology 2001; 25:816-835.
27. Gage FH. Mammalian neural stem cells. Science 2000; 287:1433-1438.
28. Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mamallian substantia nigra. Proc Natl Acad Sci USA 2003; 100:7925-7930.
29. Lie DC, Dziewczapolski G, Willhoite AR, et al. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 2002; 22:6639-6649.
30. Mao L, Lau YS, Petroske E, Wang JQ. Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration. Dev Brain Res 2001; 131:57-65.
31. Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004; 101:12543-12548. The first demonstration that dopamine neurons can be induced to form from human embryonic stem cells.
32. Munoz-Sanjuan I, Brivanlou AH. Neural induction, the default model and embryonic stem cells. Nat Rev Neurosci 2002; 3:271-280.
33. Kim TE, Lee HS, Lee YB, et al. Sonic hedgehog and FGF8 collaborate to induce dopaminergic phenotypes in the Nurr1-overexpressing neural stem cell. Biochem Biophys Res Commun 2003; 305:1040-1048.
34. Park CH, Minn YK, Lee JY, et al. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem 2005; 92:1265-1276.
35. Shim JW, Koh HC, Chang MY, et al. Enhanced in vitro midbrain dopamine neuron differentiation, dopaminergic function, neurite outgrowth, and 1-methyl-4-phenylpyridium resistance in mouse embryonic stem cells overexpressing Bel-XL. J Neurosci 2004; 24:843-852.
36. Yoshizaki T, Inaji M, Kouike H, et al. Isolation and transplantation of dopaminergic neurons generated from mouse embryonic stem cells. Neurosci Lett 2004; 363:33-37.
37. Xu H, Fan X, Wu X, et al. Neural precursor cells differentiated from mouse embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease. Biochem Biophys Res Commun 2005; 326:115-122.
38. Takagi Y, Takahashi J, Saiki H, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 2005; 115:102-109. This paper reports for the first time that stem cell transplantation can differentiate into dopamine neurons and provide clinical benefits in non-human primates.
39. Yang M, Stull ND, Berk MA, et al. Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat. Exp Neurol 2002; 177:50-60.
40. Liste I, Garcia-Garcia E, Martinez-Serrano A. The generation of dopaminergic neurons by human neural stem cells is enhanced by Bel-XL, both in vitro and in vivo. J Neurosci 2004; 24:10786-10795.
41. Carvey PM, Ling ZD, Sortwell CE, et al. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp Neurol 2001; 171:98-108.
42. Wang X, Lu Y, Zhang H, et al. Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease. Int J Dev Neurosci 2004; 22:175-183.
43. Burnstein RM, Foltynie T, He X, et al. Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson's disease. Int J Biochem Cell Biol 2004; 36:702-713.
44. Wang K, Wang JJ, Wang Y, et al. Infusion of epidermal growth factor and basic fibroblast growth factor into the striatum of parkinsonian rats leads to in vitro proliferation and differentiation of adult neural progenitor cells. Neurosci Lett 2004; 364:154-158.
45. Kishi Y, Takahashi J, Koyanagi M, et al. Estrogen promotes differentiation and survival of dopaminergic neurons derived from human neural stem cells. J Neurosci Res 2005; 79:279-286.
46. Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 2004; 113:1701-1710.
47. Medicetty S, Bledsoe AR, Fahrenholtz CB, et al. Transplantation of pig stem cells into rat brain: proliferation during the first 8 weeks. Exp Neurol 2004; 190:32-41.
48. Richards M, Fong CY, Tan S, et al. An efficient and safe xeno-free cryopreservation method for the storage of human embryonic stem cells. Stem Cells 2004; 22:779-789.
49. Brundin P, Karlsson J, Emgard M, et al. Improving the survival of grafted dopaminergic neurons: a review of current approaches. Cell Transplant 2000; 9:179-195.
50. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19:997-1005. This is an in-depth review of controversies in the use of levodopa in Parkinson's disease.
51. Fahn S, Oakes D, Shoulson I, et al., Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the Elldopa study. N Engl J Med 2004; 351:2498-2508.
52. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004; 55:761-765. An important article that discusses the limitations of pure dopaminergic therapies as treatments for Parkinson's disease where many patients suffer disability associated with degeneration in non-doparninergic regions.
53. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998; 44:175-188.
54. McNaught KStP, Perl DP, Brownell A-L, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004; 56:149-162.